Adjunctive Celecoxib in Childhood-onset OCD Study

NCT ID: NCT04673578

Last Updated: 2022-12-16

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2023-06-30

Brief Summary

This is a randomized, controlled, single-centre phase II superiority trial to determine the efficacy of 12 weeks of celecoxib (50 mg or 100 mg orally twice daily, dosed based on weight) compared to placebo as an adjunct to treatment-as-usual in children and youth with moderate-to-severe obsessive-compulsive disorder.

Detailed Description

Cyclooxygenase (COX) enzymes oxidize arachidonic acid to prostaglandins, which modulate normal neuronal function and inflammatory responses in the central nervous system. COX-2, which is constitutively expressed by glutamatergic neurons in the cortex, hippocampus, and amygdala, plays an important physiological role in synaptic plasticity and long-term potentiation. Pre-clinical studies point to a potential role for non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX enzymes, in modulation of mood and anxiety symptoms. Recent meta-analyses also suggest a role for adjunctive COX inhibitors in the treatment of depression and first-episode schizophrenia. While consensus guidelines on the use of anti-inflammatory therapy in children with acute-onset subtypes of childhood-onset obsessive compulsive disorder (OCD) suggest NSAIDs as a first-line option for patients with mild impairment, there is limited empirical evidence to support their use in this population. Two small randomized-controlled trials in adults with OCD demonstrated improved symptom severity with celecoxib - a selective COX-2 inhibitor - raising the possibility that COX inhibition may be effective in a general OCD population.

The primary objective of this study is to compare the effects of celecoxib and placebo as adjuncts to treatment-as-usual on reduction in symptom severity, as determined by Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) after 12 weeks in children and youth with moderate-to-severe OCD.

This is a randomized, controlled, single-centre superiority trial with two parallel groups (celecoxib 50 mg [≤25 kg] or 100 mg [>25 kg] twice daily and placebo). Participants will be recruited from the BC Children's Hospital (BCCH) Provincial OCD Program and based on self-referral from community practices. Randomization will be performed as block randomization with a 1:1 allocation and stratified based on pre-treatment symptom severity. The investigator, outcomes assessor, clinician, and patient will be blinded to the intervention groups. Labs at baseline and 12 weeks will include complete blood count (CBC) with differential, creatinine, electrolytes, liver enzymes, and CRP. Participants will be assessed for OCD severity and adverse events at weeks 6 and 12. Analysis will be carried out according to intention-to-treat principles. Power calculations using estimates based on previous studies suggest a target recruitment of 80 participants. Participants will be offered a 12-week open-label celecoxib extension following the blinded phase for further assessment of tolerability.

The primary outcome is OCD severity (as measured by total CY-BOCS score) after 12 weeks in the celecoxib compared to placebo arm, adjusted for baseline. Secondary outcomes include CY-BOCS score after 6 weeks adjusted for baseline OCD severity, difference in the proportion of participants achieving a clinically meaningful response or remission; mean clinical global impression of severity and improvement after 6 and 12 weeks; and difference between celecoxib and placebo arms in the proportion of participants reporting adverse events that are possibly, probably, or definitely related to the study intervention.

NSAIDs are common in clinical practice and referenced in both adult and pediatric treatment guidelines for OCD, but no controlled studies have evaluated the effects of COX inhibitors in childhood-onset OCD. This study will be the first to assess the efficacy and safety of adjunctive celecoxib in this population and will inform clinical management of children and youth with OCD.

Conditions

Obsessive-Compulsive Disorder; Pediatric Psychiatric Disorder

Keywords

Non-steroidal anti-inflammatory drug; Cyclooxygenase inhibitor; Celecoxib; Inflammation; Children; Obsessive-compulsive disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Celecoxib

Celecoxib 50 mg orally twice daily (if weight 10-25 kg) or 100 mg orally twice daily (if weight \> 25 kg) for 12 weeks. Used as adjunct to treatment-as-usual.

Group Type: EXPERIMENTAL

Celecoxib

Intervention Type: DRUG

Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)

Placebo (microcrystalline cellulose)

Placebo capsules identical to celecoxib. One capsule orally twice daily for 12 weeks. Used as adjunct to treatment-as-usual.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Microcrystalline cellulose

Interventions

Celecoxib

Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)

Intervention Type: DRUG

Placebo

Microcrystalline cellulose

Intervention Type: OTHER

Other Intervention Names

MINT-CELECOXIB; NDC Code: 0025-1525; ATC Code: M01AH01; Canadian DIN: 02412497

Eligibility Criteria

Inclusion Criteria

1. Age 7-18 years

2. Resident of British Columbia

3. DSM-5 diagnosis of OCD based on (a) history of prior clinician assessment and (b) standardized interview

4. CY-BOCS score ≥16 (moderate to severe)

5. Able to take medication twice daily in capsule form (in whole form or sprinkled contents)

6. Negative pregnancy test (either serum or urine) in participants with child-bearing potential

7. Use of highly effective and/or double barrier contraception, or abstinence, in participants with child-bearing potential

Exclusion Criteria

1. Lifetime diagnosis of renal disease, liver disease, gastrointestinal bleeding, peptic ulcer disease, inflammatory bowel disease, severe or uncontrolled asthma, bleeding disorders, heart disease, heart failure, or hypertension

2. Current major depressive episode, acute psychosis, active substance use, suicidality, or restriction of fluid intake

3. Pregnant or breastfeeding during the study period

4. Active infection or antibiotic treatment at baseline

5. Allergy to celecoxib, sulfonamide compounds, or NSAIDs, including aspirin

6. Current or previous regular use of immune-modulating therapies for treatment of OCD symptoms, at an effective anti-inflammatory dose (including NSAIDs, corticosteroids, or biologics)

7. Use of NSAIDs at any dose at a frequency ≥ 3 times per week during the 2 months prior to randomization

8. Current use of intravenous or oral corticosteroids

9. Concurrent use of CYP2C9 inhibitors fluconazole, amiodarone, oxandrolone or methotrexate; CYP2C9 inducers including rifampin and phenobarbital; or any other drug that may interact with celecoxib and, in the opinion of Dr. Stewart or another study investigator, represents a potential safety risk

10. Poor CYP2C9 metabolizer (i.e. CYP2C9*3/*3 genotype) based on clinical suspicion or previous genotyping.

11. Abnormality identified on baseline serology including leukocytosis, leukopenia, thrombocytopenia, anemia, abnormal renal function (Cr > 1.5 x upper limit of normal), or abnormal liver function (ALT, ALP, or AST > 1.5x upper limit of normal)

12. New psychotropic medication (i.e. medication with known or potential impact on psychiatric symptoms, including selective serotonin reuptake inhibitors, benzodiazepines, antipsychotics, stimulants, anticonvulsants, mood stabilizers, or other medications) or other ongoing regular medication started in the 10 weeks prior to baseline, or change in dose in the 4 weeks prior to baseline

13. Changes in CBT or other psychotherapy in the 4 weeks prior to baseline (i.e. change in regular frequency, modality, or care provider)

14. Notable other treatment changes during the study period (either pharmacotherapy or psychotherapy)

15. No regular physician (family doctor or specialist) providing usual medical care

16. Participant/parents unable to provide informed consent or assent or participate in self-care, AE reporting, or follow-up assessments

17. Inability to have blood pressure measured within 2 months prior to enrollment (either on-site at BCCH or by a primary care provider).

18. Intention of pregnancy in participants with child-bearing potential.

• Minimum Eligible Age: 7 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BC Children's Hospital Research Institute

OTHER

Sponsor Role: collaborator

Obsessive Compulsive Foundation

OTHER

Sponsor Role: collaborator

University of British Columbia

OTHER

Sponsor Role: lead

Responsible Party

Evelyn Stewart, MD

Professor, Division of Clinical & Behavioural Neurosciences, Department of Psychiatry, Faculty of Medicine; Medical Director, BCCH Provincial OCD Program (POP); Investigator, BC Children's Hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

S. Evelyn Stewart, MD

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia; BC Children's Hospital Research Institute

Clara Westwell-Roper, MD, PhD

Role: STUDY_CHAIR

University of British Columbia; BC Children's Hospital Research Institute

Locations

BC Children's Hospital Research Institute

Vancouver, British Columbia, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Research Assistant, Provincial OCD Program

Role: CONTACT

Phone: 604-875-2000

Email: aceocd@bcchr.ca

S. Evelyn Stewart, MD

Role: CONTACT

Phone: 604-875-2000

Email: estewart@ubc.ca

Facility Contacts

Zainab Naqqash, BA

Role: primary

References

Westwell-Roper C, Best JR, Elbe D, MacFadden M, Baer S, Tucker L, Au A, Naqqash Z, Lin B, Lu C, Stewart SE. Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive-compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study. BMJ Open. 2022 Jan 31;12(1):e054296. doi: 10.1136/bmjopen-2021-054296.

Reference Type: DERIVED

PMID: 35105633 (View on PubMed)

Other Identifiers

H19-03886

Identifier Type: -

Identifier Source: org_study_id